EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues
NRx Pharmaceuticals, Inc. (NRXP) had EBITDA Margin of -1312.73% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$1.23M |
|
$-28.62M |
|
$0.51M |
|
$0.72M |
|
$17.45M |
|
$-16.22M |
|
$-12.40M |
|
$-28.62M |
|
$-28.59M |
|
$-28.62M |
|
$-28.62M |
|
$-28.62M |
|
$-28.59M |
|
$-16.22M |
|
$-16.08M |
|
21.40M |
|
21.40M |
|
$-1.34 |
|
$-1.34 |
|
| Balance Sheet Financials | |
$8.89M |
|
$0.06M |
|
$4.06M |
|
$12.96M |
|
$28.58M |
|
-- |
|
$0.32M |
|
$28.89M |
|
$-15.94M |
|
$-18.66M |
|
$-15.94M |
|
31.73M |
|
| Cash Flow Statement Financials | |
$-14.11M |
|
$-2.81M |
|
$23.28M |
|
$1.44M |
|
$7.80M |
|
$6.35M |
|
$0.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.31 |
|
-- |
|
-- |
|
-- |
|
-- |
|
58.78% |
|
-1324.41% |
|
-1324.41% |
|
|
EBITDA Margin |
-1312.73% |
-2336.49% |
|
-2336.49% |
|
$-14.11M |
|
-- |
|
-- |
|
-- |
|
0.09 |
|
-- |
|
7.61 |
|
47.97 |
|
179.59% |
|
153.43% |
|
-220.92% |
|
179.59% |
|
$-0.50 |
|
$-0.66 |
|
$-0.66 |
|